High Complete Response and Durability in TAR-200 SunRISe-1 Cohort 2

The Phase 2b SunRISe-1 trial presented compelling findings at the 2024 ESMO Congress, showcasing TAR-200’s notable effectiveness as monotherapy for patients with high-risk, non-muscle invasive bladder cancer (HR-NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). Out of the studied cohort, TAR-200 achieved a remarkable complete response (CR) rate of 83.5%, substantially surpassing previously available therapies. Significantly, the durability of the therapeutic effect was equally impressive, with 82% of responders maintaining remission at 9 months, and an estimated 12-month complete response rate of 57%. This indicates a robust and lasting impact on disease management. The safety profile further strengthened TAR-200's clinical appeal, demonstrating a low incidence (9%) of Grade ≥3 treatment-related adverse events (TRAEs), minimal treatment discontinuation (6%), and no treatment-related fatalities. Such outcomes significantly enhance TAR-200’s position as a promising therapeutic option, potentially transforming patient management paradigms in HR-NMIBC.

Citation: Johnson & Johnson Investor Report, 2024. Available at: https://www.investor.jnj.com

Implication: TAR-200’s strong efficacy and excellent safety profile could significantly alter standard treatment protocols, providing clinicians with a reliable new therapy.